Culmerciclib: First Approval

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer often develops resistance to standard endocrine therapy.
• Cyclin-dependent kinases (CDKs) 2, 4, and 6 play crucial roles in cell cycle progression and are implicated in endocrine therapy resistance.
• Targeting multiple CDKs simultaneously may offer a strategy to overcome resistance mechanisms in breast cancer.

Purpose of the Study:

• To summarize the key milestones in the development of culmerciclib, a novel oral small molecule inhibitor of CDK2/4/6.
• To highlight the regulatory approval of culmerciclib in China for a specific breast cancer patient population.

Main Methods:

• Review of preclinical and clinical development data for culmerciclib.
• Analysis of regulatory submission and approval process in China.

Main Results:

• Culmerciclib, an oral small molecule inhibitor targeting CDK2, CDK4, and CDK6, has been developed by Chia Tai Tianqing Pharmaceutical.
• The drug received its first marketing approval in China on December 9, 2025.
• Approval is for the treatment of adults with HR+/HER2- advanced or metastatic breast cancer who have progressed after endocrine therapy, in combination with fulvestrant.

Conclusions:

• Culmerciclib represents a significant advancement in the treatment of endocrine-resistant HR+/HER2- advanced or metastatic breast cancer.
• The simultaneous inhibition of CDK2/4/6 by culmerciclib offers a potential strategy to overcome resistance mechanisms.
• This first approval marks a major milestone for culmerciclib and provides a new therapeutic option for patients in China.